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Abstract
Aim : To compare responses to therapy of Black African (BA) 
and non-Black African (non- BA) patients with hepatitis C virus 
genotype 4 (HCV-4) residing in Belgium.
Methods : In this retrospective multicenter study, 473 patients 
with HCV-4 were selected from databases at 7 Belgian centers ; 
209 treatment-naïve patients (154 BA) had received treatment with 
peg-interferon (peg-IFN) plus ribavirin (RBV) and were included 
in the study.
Results : There was a greater percentage of female patients in the 
BA group than in the non- BA group ; BA patients were also older, 
had a greater body mass index, and more frequently had abnormal 
glucose metabolism. The route of contamination was more fre-
quently unknown in BA than in non-BA patients and BA patients 
had more HCV-4 subtypes. There were no differences in other de-
mographic factors between the groups. Sustained viral response 
(SVR) and complete early viral response rates were significantly 
lower and relapse rates significantly higher in BA than in non-BA 
patients. There were no differences between groups in rates of dose 
modification or in drug tolerance.
Conclusion : In our cohort, treatment-naïve BA patients with 
HCV-4 who were treated with peg-IFN and ribavirin had a much 
lower SVR rate than treatment-naïve non-BA patients with HCV-
4 who were treated with peg-IFN and ribavirin, and a higher 
 relapse rate, possibly related to a weaker response to interferon-
based therapy. Treatment may need to be adapted in this popula-
tion. (Acta gastro enterol. belg., 2013, 76, 291-299).
Key words : Black Africans, hepatitis C virus, antiviral therapy, geno-
type 4.
Introduction
Hepatitis C virus (HCV) infection is frequent among 
the population of central Africa, with a prevalence of 
6%. The predominant genotype in this region is genotype 
4 (HCV-4) (1-3). However, response to therapy in pa-
tients with HCV-4 has been studied mainly in other pop-
ulation groups, for example, in patients from Egypt and 
the Middle East ; in these populations, sustained viral 
response (SVR) rates of 58 to 76% have been ob-
served (4). There are few studies on therapeutic response 
in Black Africans (BA) with HCV-4. In a study conduct-
ed in France, which compared therapeutic responses in 
three ethnic groups infected with HCV-4, only 37 BA 
patients were included in the analysis of therapeutic 
data ; the SVR rate of the BA patients in this study was 
32.4% (5).
It has been postulated that response to antiviral ther-
apy in HCV-infected patients vary according to ethnic 
and/or racial group. Indeed, in the US, an ethnic/racial 
difference in SVR rates (28% and 52%, respectively) 
was demonstrated in African Americans and non-African 
Americans infected with HCV genotype 1b (HCV-
1b) (6) ; there was also a difference in SVR rates (34% 
vs. 49%) between Latin and non-Latin carriers of HCV-1 
infection (7). It remains unclear whether these differenc-
es in viral response are related to host factors (ethnicity, 
human immunodeficiency virus [HIV] co-infection, 
overweight/obesity, insulin resistance, cirrhosis, and ge-
netic polymorphism for IL28B) or to virus-related fac-
tors (HCV subtypes, viral load) (6,8-10).
Because of the cost of HCV therapy, it is unlikely 
that large-scale therapeutic trials will be conducted in 
sub-Saharan Africa to evaluate responses to therapy of 
BA patients infected with HCV-4. However, it is possi-
ble to study the therapeutic response in BA patients 
 infected with this genotype who have immigrated to 
 European countries.
Our aim, therefore, was to compare the response 
rate to peg-interferon (peg-IFN) plus ribavirin (RBV) 
therapy in treatment-naïve HCV-4 BA and non-BA 
 patients living in Belgium.
Patients and Methods
Patient selection
The study was conducted in conformity with the 
principles of the Declaration of Helsinki and local laws 
and regulations. The institutional review boards of the 
participating centers and the ethical Committee of the 
principal investigating center (CHU Saint-Pierre, Brus-
sels, OM 007) approved the study protocol.
Patients with HCV-4 infection were identified from 
databases at 7 Belgian centers (CHU Saint-Pierre, CHU 
Brugmann, Hôpital Erasme, Hôpital Bracops and CH 
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derwent one or more tolerance assessments were includ-
ed in the drug tolerance analyses. Drug tolerance was 
assessed by the physician, who recorded adverse effects 
reported by each patient as well as clinical and labora-
tory results. Drug tolerance was classified as good (no 
need for dose reduction or treatment withdrawal) or poor 
(symptomatic adverse effects necessitating dose reduc-
tion or treatment withdrawal).
Baseline parameters
The following baseline parameters were recorded : 
ethnic origin (a BA was defined as an individual from 
Central Africa whose parents were both BA ; the non-BA 
category included mainly Caucasian whites, North Afri-
cans and Turks) ; sex ; age at start of treatment ; body 
weight (kg) ; body mass index (BMI) (kg/m2) ; risk fac-
tors for infection ; co-morbidity, including arterial hyper-
tension (treated or arterial pressure > 130/85 mmHg), 
dyslipidemia (treated or above the upper limit of normal 
[ULN] for serum cholesterol and/or triglycerides), im-
paired glucose metabolism including intolerance (fast-
ing glycemia > 100, but < 125 mg/dL) and overt diabe-
tes (treated or not), kidney failure (if serum creatinine 
was over the ULN) ; alcohol consumption (classified as 
never, occasional [less than or equal to 2 drinks per 
month], active/daily [more than 2 drinks per month or 
1 drinks per day], past intake [no drink in the year 
 preceding inclusion]) ; co-infection with hepatitis B virus 
(HBV, presence of HBs antigen) and/or HIV (positive 
antibodies and viremia) ; HCV-4 viral load (< or 
≥ 400,000 IU/mL) and viral subtypes ; alanine trans-
aminase (ALT) quotient (ALT level divided by the 
ULN) < or > 2, and persistently normal ALT (pNALT) 
over a 6- to 12-month period.
Liver biopsy specimens obtained before treatment, 
were evaluated using the METAVIR classification for 
activity grade (A), liver fibrosis stage (F), and degree of 
steatosis (16,17). A central review of biopsies was not 
performed. The following groups were distinguished : 
METAVIR grade (A) < 2 and ≥ 2 ; METAVIR stage (F) 
< 2 and ≥ 2 ; degree of steatosis < 10%, 10 to 30%, 
> 30%.
Virology tests
Quantitative tests measuring HCV RNA levels (ex-
pressed in IU/ml) were performed using a Cobas Ampli-
cor HCV monitor, version 2.0 (Roche Systems), a Ver-
sant HCV RNA 3.0 assay (Bayer HealthCare) or the 
Cobas Taqman HCV test (Roche Systems) and Abbott 
Real Time (Abbott Diagnostic). Qualitative tests were 
performed using a Cobas Amplicor HCV monitor, ver-
sion 2.0 (Roche Systems) or an Amplicor HCV moni-
tor, version 2.0. The HCV limit of detection in qualita-
tive assays was ≤ 50 IU/mL. Genotyping was performed 
using assays from INNO-LIPA HCV II (Innogenetics, 
Ghent, Belgium) and the Versant HCV genotyping assay 
(Bayer HealthCare).
Molière, Brussels ; CHU Sart Tilman, Liège ; University 
Hospital Antwerp). These centers are located in the 3 
largest Belgian cities and most patients were from Brus-
sels. Patients were selected for the study if they were 
aged 18 years, had HCV-4 infection, and were treat-
ment-naïve before being treated with peg-IFN plus RBV 
with or without amantadine (AM) between 1999 and 
2006.
Study design
The criteria for starting antiviral therapy in Belgium 
follow international guidelines (11-14). IFN alpha-2a or-
2b alone was given between 1992 and 2000, and IFN in 
association with RBV from 2001 to 2004. Since 2004, 
standard care consists of the association of peg-IFN al-
pha-2a or-2b plus RBV. Some patients received AM 
(200 mg daily) in addition to standard peg-IFN and RBV 
in the context of a Belgian clinical trial. Because it has 
been shown that AM has no effect on the SVR (15), we 
kept these cases in the study.
The duration of planned therapy was 48 weeks what-
ever the treatment. Criteria for stopping treatment were 
in accordance with international guidelines issued from 
1999 to 2006, notably absence of a 2 log decrease in 
viral load at week 12 of antiviral treatment or a detect-
able viral RNA in the blood at week 24 of antiviral 
treatment.
Patients were divided into two groups according to 
their ethnic origin – BA and non-BA – and the two 
groups were compared in terms of epidemiological 
and demographic features, response and tolerance to 
therapy, and need for dose reduction. Factors predictive 
of viral response were also analyzed.
A patient was considered lost to follow-up when he/
she no longer attended the viral and/or clinical check-up, 
and as a non-responder if he/she did not show a decrease 
in viral load > 2 log at week 12 (= primary non-response), 
had detectable HCV RNA after 24 weeks of therapy, or 
had detectable HCV RNA at the end of treatment.
Endpoints and assessments
Efficacy endpoints consisted of viral responses as fol-
lows :
- SVR, defined as undetectable HCV RNA levels 24 
weeks after the end of the treatment period (week 
72), and relapse (REL), assessed between the end 
of treatment and 24 weeks later ;
- early viral response (EVR) : negative qualitative 
PCR or a decrease in HCV RNA levels equal to more 
than 2-log10 after 12 weeks ; complete EVR (cEVR) : 
undetectable HCV RNA levels at week 12 ;
- viral response at end of treatment : undetectable HCV 
RNA levels at week 48.
All enrolled patients who had been treated for at least 
12 weeks were included in the efficacy evaluations. All 
patients who received one or more doses of IFN and un-
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There were no significant differences between the 
groups in frequency of co-infection with HBV and HIV, 
dyslipidemia, alcohol intake, transaminase levels, 
METAVIR score for activity or fibrosis, degree of liver 
steatosis or viral load.
Treatment, doses and tolerance (Table 2)
Within the study population of treatment-naïve patients 
(Fig. 1) :
- HCV RNA monitoring was not performed : at week 
12 in 23 patients (16 BA and 7 non- BA) because of 
loss to follow-up (6 BA and 4 non-BA), or treatment 
withdrawal (10 BA and 3 non-BA) ;
- treatment was discontinued because of primary non-
response in 37 BA and 11 non-BA patients at week 
12, or non-response at week 24 in 15 BA and 2 non-
BA patients. Other reasons for discontinuation of 
treatment included : thyroid dysfunction (1 BA), 
 psychological complication (1 non-BA), lack of 
 compliance (1 BA), travel to a foreign country (1 BA), 
asthenia (1 non-BA) or death (1 BA after liver trans-
plantation and 1 non- BA from unknown cause).
There were no significant differences in type of treat-
ment and dose reduction because of adverse events be-
tween the groups, and drug tolerance was similar. No 
tolerance details were available for 53 patients (37 BA 
and 16 non-BA).
Viral responses (Table 3)
The SVR rate was lower in BA patients than in non-
BA patients (p = 0.002) because of the higher rate of re-
lapse in BA compared to non-BA patients (p = 0.03). 
There was a lower response rate at the end of treatment in 
BA than in non-BA patients (p = 0.08). More non-BA 
patients had a complete EVR than did BA patients 
(p = 0.02), but the overall EVR was not significantly dif-
ferent in non-BA and BA patients [37/48 (77.1%) vs. 
101/138 (73,2%), OR and 95%CI 0.81 (0.37-1.75), 
p = 0.5]. In both groups, SVR rates were similar in pa-
tients treated with peg-IFN+RBV without AM compared 
to those treated with peg-IFN+RBV plus AM : in BA, 
30/112 (26.5%) vs. 9/25 (36%) ; and in non-BA, 21/41 
(53.6%) vs. 2/5 (40%).
Viral outcome according to METAVIR fibrosis stage 
(Fig. 2)
In patients with bridging fibrosis (stage F3) or cirrho-
sis (stage F4), the SVR rate was 3/29 (10.3%) in BA pa-
tients compared to 5/10 (50%) in non-BA patients [OR 
0.11 (0.02-0.64), p = 0.007]. In patients with mild to 
moderate fibrosis (stage F0 to stage F2), the SVR was 
also lower in BA than in non-BA patients [34/102 (33.3%) 
vs. 18/32 (56.2%), OR 0.38 (0.17-0.87), p = 0.02].
Factors predictive of viral response in univariate and 
multivariate analyses (Table 4).
Statistical analysis
Baseline characteristics are presented as number of 
cases and percentages for categorical data, and as means 
and ranges for continuous data. Patient groups were com-
pared using either Fisher’s exact test or chi-square (for 
categorical variables with more than two levels). Con-
tinuous variables were compared using a Student’s t test. 
Between-group differences are presented as the differ-
ence between means of each group, with a 95% CI for 
each comparison. A crude odds ratio (OR) is presented 
for each comparison. Each OR is presented with its 95% 
CI.
The primary efficacy endpoint was also assessed us-
ing multivariable logistic regression analysis to evaluate 
the effects of baseline prognostic factors on the probabil-
ity of an SVR. To identify factors associated with rates 
of SVR, ORs adjusted for factors with a p value equal 
or less than 0.1 in crude (unadjusted) analysis were cal-
culated.
Computerized procedures were performed using SPSS 
for Windows version 17.0 (SPSS Inc., Chicago, IL, 
USA).
Results
Types of treatment in the entire HCV-4 infected group
Among 473 patients identified with HCV-4 infection 
(331 BA and 142 non-BA), 273 (195 BA and 78 non-
BA) had received treatment : 58 patients (37 BA and 
21 non-BA) received IFN with or without RBV, 209 
treatment-naïve patients (154 BA and 55 non-BA) and 6 
treatment-experienced patients (4 BA and 2 non-BA) 
received Peg-IFN with or without AM. The BA patients 
were from Central Africa, including the Democratic Re-
public of Congo (two-thirds), Angola, Burundi, Camer-
oon, Gabon and Rwanda. Non-BA patients included 
white Caucasians, primarily from European countries 
(two-thirds), including Belgium, France, Greece, Italy, 
Portugal, Spain and Russia, or North Africa, including 
Morocco, Algeria, Egypt and Tunisia.
Baseline characteristics of the treatment-naïve popula-
tion (n = 209) treated with peg-IFN plus RBV with or 
without AM (Table 1)
Two hundred and nine treatment-naïve patients (154 
BA and 55 non-BA) were treated with peg-IFN plus 
RBV (126 BA, 47 non-BA) or peg-IFN plus RBV plus 
AM (28 BA, 8 non-BA) and formed the study group. BA 
patients were more frequently female (p < 0.0001), were 
significantly older than non-BA patients, and had a sig-
nificantly higher BMI. The most frequent mode of trans-
mission in BA patients was unknown (63%) compared to 
non-BA patients in whom intravenous drug use was the 
most frequent mode of transmission (45%). Glucose in-
tolerance abnormalities and viral subtypes were signifi-
cantly more frequent in BA than in non-BA patients.
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Discussion
This retrospective study comprises the largest series to 
date of BA patients treated for HCV-4 infection. Our 
study indicates that treatment-naïve HCV-4 infected BA 
patients living in Belgium have a significantly lower 
SVR rate following treatment with peg-IFN plus RBV 
than do treatment-naïve non-BA patients : 28% vs. 52%, 
respectively. This lower SVR rate in BA patients was the 
result of a slower viral response (with a less complete 
In univariate analysis, baseline factors studied were 
ethnicity, gender, age, weight, HIV status, METAVIR 
fibrosis stage, HCV-4 subtypes, pretreatment viral load, 
drug tolerance, and complete EVR. BA ethnicity, age 
> 40, HIV-positive status, viral load > 400000, subtypes 
other than 4c/4d, METAVIR fibrosis stage > 2, and par-
tial EVR were associated with a lower SVR rate.
In multivariate analysis, BA ethnicity, HIV infection, 
viral load > 400000, and partial EVR were independent 
predictors of poor response.
Table 1. — Baseline characteristics of 209 treatment-naïve patients treated with peg-IFN plusRBV with or without 








Male gender n (%)
Age at treatment (years)


















Patients with weight of ≥ 70 kg (n* = 48/138) 30 (62.5%) 138 (100%) 5.6 (4.04 to 7.75) < 0.0001
Body mass index (kg/m2 )







Contamination risk factor (n* = 49/152)
  Transfusion 












HBs antigen + ve 13 (23.6%) 40 (26%) 1.13 (0.55 to 2.32) 0.85
HIV + ve (n*=51/152) (%) 9 (17.65%) 19 (12.5%) 0.66 (0.28 to 1.58) 0.35
Glucose intolerance or diabetes (n* = 45/134) (%) 6 (13.3%) 38 (28.4%) 2.57 (1.00 to 6.50) 0.04
Dyslipidemia (n* = 43/121) (%) 8 (18.6%) 27 (22.3%) 1.25 (0.52 to 3.02) 0.61












8 (6.9%)      
} 0.27
ALT (n* = 52/147) (%)
  Persistently normal ALT






METAVIR score (n* = 52/145) (%)
  ≥ A2





1.41 (0.71 to 2.83)
0.16 (0.84 to 3.1)
0.32
0.14
Degree of liver steatosis (n*=45/108) (%)
  < 10%
  10% to 30%






5 (4.6%)      } 0.25
Subtype (n = 55/153)
  4a; 4c/4d
  4e; other
0; 26 (47.2%)
1 (1.8%); 27 (49%) 
8 (3.85%); 15 (9.8%)
26 (17%); 102 (66.6%)      } < 0.001
Viral load (× 103 IU/mL) (n* = 51/141)







Viral load > 400,000 IU/ml (n = 51/141) (%) 35 (68.6%) 101 (71.6%) 0.90
a In each group, data are presented as number of cases (percentages) ; bCI, confidence interval ; cP value comparing non- BA group versus  BA 
group ; n*: number of cases for which data were available in each group, non-BA/BA ; SD: standard deviation ; +ve-positive ; ** Number of patients 
with a METAVIR fibrosis stage of 3 or 4 was 29/145 (20%) in BA and 10/45 (22.2%) in non-BA respectively.
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Age and viral load were also independent predictors 
of response. The fact that our BA patients were older 
than our non-BA patients may thus, in part, explain our 
observation of hyporesponsiveness among BA patients. 
Concerning the viral load, we observed that a viral load 
equal to or greater than 400000 IU/mL was associated 
with a worse response ; other trials have shown similar 
results (4,6,8,18).
Liver fibrosis is another factor that has been consis-
tently shown to affect SVR (6,8,29). In our study, we 
observed only a trend because of the limited sample 
size. The stage of bridging fibrosis and cirrhosis was 
similar in BA and non-BA patients, but the SVR rate 
was significantly lower in BA patients with bridging 
fibrosis/cirrhosis than in non-BA patients with bridging 
fibrosis/cirrhosis. Similarly, in patients with mild liver 
disease, BA patients were more often hyporesponsive 
than were non-BA patients. We also demonstrated that 
infected patients with cirrhosis can achieve an SVR, in 
line with a recent study by Bruno et al. (30).
In our study, BA patients were more commonly fe-
male, weighed more, and had more viral subtypes than 
did the non-BA patients, but these factors did not explain 
the difference in response between the two groups after 
adjustment for multiple factors. However, male gender, 
obesity, and non-4a viral subtype have been associated 
with a lower SVR in other studies. Other factors related 
to treatment, such as drug tolerance or therapeutic dose, 
cannot explain the difference in SVR we observed, be-
cause these factors were similar in our two groups of 
patients. Nevertheless, it is well established that a maxi-
mum therapeutic dose taken for a maximum time period 
is essential to achieve an SVR (5,6,8,29,31).
BA and non-BA patients were similarly co-infected 
with HBV. Moreover, the SVR rates were 8/24 (33%) in 
co-infected BA and 3/6 (50%) in co-infected non-BA pa-
tients, which were not significantly different from each 
other (p = 0.09). This response rate in co-infected pa-
tients is close to the average response rate in each HCV 
mono-infected group. Although our results are limited 
because of the small number of HBV-HCV co-infected 
patients, Chuang et al. showed that HBV-HCV-1-co- 
infected patients treated with IFN plus RBV had a 
EVR) leading to a higher rate of relapse (43% vs 19%) ; 
the rate of non-response was similar in the two groups. 
Importantly, in univariate and multivariate analyses, 
BA ethnicity and partial EVR were good predictors of a 
poor SVR.
Similar observations have been reported in the US, 
where a trend toward a higher relapse rate was found in 
African Americans compared to Caucasian Ameri-
cans (6). Because many African Americans are descen-
dants of BA individuals, it is presumed that their genetic 
background is likely to be similar. The reason for hypo-
responsiveness in African Americans and BA patients 
residing in Europe is not known, but may be related to 
different interactions between viral and host factors (non-
modifiable and modifiable) (18,19).
HCV genetic diversity within isolates may modulate 
sensitivity to IFN (20). Non- modifiable host factors, in-
cluding IFN-stimulated gene transcription (higher in 
Caucasian Americans than in African Americans) and 
genetic polymorphism in the IL28B gene encoding 
IFN-λ-3 (associated with a twofold greater response to 
therapy in Caucasians versus African Americans), may 
also be involved (10,21). Recently, in France, an associa-
tion between the IL28B polymorphism and treatment 
response was demonstrated in patients with HCV4 in-
fection. It would have been interesting to perform this 
test for polymorphism in the IL28B gene in our study ; 
however, our study was carried out before Ge et al. pub-
lished their results. Moreover, patient DNA, mandatory 
for sequencing genes, was not available, because our 
study was retrospective and multicenter. Additional im-
munogenetic factors may also be involved, including hu-
man leukocyte antigen class II, nucleotide polymorphism 
for immune genes and T lymphocyte natural killer recep-
tors (21-25).
In multivariate analysis, we found that, in addition 
to ethnicity, concomitant HIV infection was an indepen-
dent predictor of a poor SVR. HIV infection significant-
ly impaired the SVR rate of our patients, similar to ob-
servations in other studies (26-28). Nevertheless, even 
after exclusion of HIV infection as a confounding fac-
tor, ethnicity was a predictor of SVR [OR 0.33 (0.10 to 
1.04), p = 0.05].
Table 2. —  Treatment type, dose, and adverse effects in 209 treatment-naïve patients treated with peg-IFN plus 
RBV with or without AM, stratified according to ethnicity: non-Black African (non-BA) versus Black African (BA)
Patient characteristics non-BA BA OR
(95%CI)
p-Value
Type of treatment -n (%)
  PEG + RBV





0.76 (0.32 to 1.79)
1.30 (0.55 to 3.06)
0.53
0.53
Dose reduction because of adverse events
  Peg-IFN - n (%)





1.8 (0.83 to 3.88)
1.63 (0.75 to 3.53)
0.15
0.27
Tolerance to treatment -n (%)
   (good vs. poor) 28/38 (73.6%) 77/117 (65.8%) 0.68 (0.30 to 1.55) 0.412
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Fig. 1. — Study design : Among 473 patients with HCV-4, 273 received treatment. We studied the subgroup of 209 treatment-naïve 
patients who had been treated with peg-IFN + RBV.
Excluded : did not fulfil 
inclusion criteria, or
treated with IFN or IFN 
plus RBV
N = 264








Completed week 48 of
therapy
n = 32



















Completed week 12 of
therapy
n = 138







therapy due to non-
response, adverse
effects :
16 non-BA, 56 BA
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liminary data from next-generation agents currently un-
der development against HCV-4 (e.g., TMC 435) are 
encouraging (33). Other strategies, including better man-
agement of host-modifiable factors or treatment prolon-
gation in case of slow response, as suggested for geno-
type 1, could be proposed. Therapy with nitazoxanide 
(a new activator of IFN-induced mediators that has 
demonstrated efficacy against HCV-4) and with newer 
molecules targeting viral machinery or based on host 
genes should be studied in the BA population (34-36).
In conclusion, this study demonstrates that treatment-
naïve BA patients with HCV-4 who were treated with 
peg-IFN and RBV had a much lower SVR rate than did 
treatment- naïve non-BA patients with HCV-4. This 
lower SVR rate was associated with a higher relapse 
rate, probably related to a slower viral response to IFN-
based therapy. The mechanism behind this observation 
has not been clearly elucidated, but may be related to 
 response comparable to that of HCV-1 mono-infected 
patients (32).
The SVR rate among BA patients was lower than that 
observed in Egyptian and Middle Eastern patients treat-
ed with peg-IFN and RBV (from 54% to 80%). The 
reason for this difference is unclear. Some possible ex-
planations were presented earlier in the discussion sec-
tion. Another potential reason may be related to the 
HCV-4 subtype. Indeed, although no subtype was pre-
dictive of response in our study, in Egyptian studies sub-
type 4a was most prevalent and was associated with a 
more favorable viral response (4,5). Additional factors, 
such as the number of patients with cirrhosis, along with 
environmental factors, may play a role in this difference 
in response rate between our BA patients residing in 
Belgium and patients from Egypt and the Middle East.
The results of our study reveal that the need for better 
anti-HCV therapy is greater than ever in populations in-
fected with HCV-4, particularly those of BA origin. Pre-
Table 3
Response Ethnicity OR 95% CI p-Value
(type) Overall non-BA BA
EVR 138/186 (74.2%) 37/48 (77.1%) 101/138(72.8%) 0.81 0.37-1.75 0.53
cEVR 62/186 (33.3%) 22/48 (45.8%) 40/138 (29.0%) 0.48 0.24 – 0.94 0.02
EOT VR 98/186 (52.7%) 31/48 (64.6%) 67/138 (48.6%) 0.51 0.26 – 1.02 0.05
Relapse 34/98 (34.7%) 6/31 (19.3%) 28/67 (42.6%) 0.33 0.12 – 0.92 0.03
SVR 64/186 (34.4%) 25/48 (52.0%) 39/138 (28.3%) 0.36 0.18 – 0.72 0.002
complete, ; EVR: early viral response ;  EOT VR: end of treatment viral response ; SVR: sustained viral response ; OR and 95% CI: odds ratio and 
95% confidence interval.
Fig. 2. — Viral outcome according to the METAVIR stage of fibrosis
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genetic or purely ethnic differences between the two 
groups, suggesting that the therapeutic regimen may 
need to be adapted in BA populations.
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